Literature DB >> 16715036

The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma.

Aqeel M Siddiqui1, Xiaoxuan Cui, Rongqian Wu, Weifeng Dong, Mian Zhou, Maowen Hu, H Hank Simms, Ping Wang.   

Abstract

OBJECTIVE: Although phytochemical curcumin has been shown to possess anti-inflammatory properties, it remains unknown whether this agent has any beneficial effects in sepsis. The purpose of this study was to demonstrate whether curcumin protects septic animals and, if so, whether activation of peroxisome proliferator-activated receptor (PPAR)-gamma, an anti-inflammatory nuclear receptor, plays any role.
DESIGN: Prospective, controlled, and randomized animal study.
SETTING: A research institute laboratory.
SUBJECTS: Male Sprague-Dawley rats.
INTERVENTIONS: A bolus injection of 0.2 micromol of curcumin was given intravenously to male adult rats, followed by continuous infusion of curcumin (0.24 micromol/day) for 3 days via a primed 2-mL mini-pump. The rats were then subjected to sepsis by cecal ligation and puncture (CLP).
MEASUREMENTS AND MAIN RESULTS: Serum levels of liver enzymes (alanine aminotransferase and aspartate aminotransferase), lactate, albumin, and tumor necrosis factor (TNF)-alpha were measured at 20 hrs after CLP (i.e., late stage of sepsis). In addition, a 10-day survival curve was conducted following CLP and cecal excision with or without curcumin treatment. Furthermore, macrophages cell line RAW 264.7 cells were treated with curcumin followed by stimulation with endotoxin. TNF-alpha and PPAR-gamma expression were then measured. The results indicate that intravenous administration of curcumin before the onset of sepsis attenuated tissue injury, reduced mortality, and decreased the expression of TNF-alpha in septic animals. Similar results were also found when curcumin was administered after the onset of sepsis. Moreover, the down-regulated PPAR-gamma in the liver at 20 hrs after CLP was significantly improved by curcumin treatment. Concurrent administration of curcumin and GW9662, a specific PPAR-gamma antagonist, completely abolished the beneficial effects of curcumin under such conditions. In cultured RAW 264.7 cells, curcumin inhibited endotoxin-induced increases in TNF-alpha expression and markedly up-regulated PPAR-gamma expression without affecting cell viability. Curcumin also prevented morphologic alterations in macrophages induced by endotoxin.
CONCLUSIONS: The protective effect of curcumin makes it or its analogues strong candidates as a novel therapy for sepsis. The beneficial effect of curcumin appears to be mediated by up-regulation of nuclear receptor PPAR-gamma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715036     DOI: 10.1097/01.CCM.0000221921.71300.BF

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  56 in total

1.  Peroxisome proliferator activated receptor-γ and traumatic brain injury.

Authors:  Lei Qi; Asha Jacob; Ping Wang; Rongqian Wu
Journal:  Int J Clin Exp Med       Date:  2010-09-23

Review 2.  Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis.

Authors:  Haim Shapiro; Pierre Singer; Zamir Halpern; Rafael Bruck
Journal:  Gut       Date:  2006-08-24       Impact factor: 23.059

3.  Acceleration of wound repair by curcumin in the excision wound of mice exposed to different doses of fractionated γ radiation.

Authors:  Ganesh Chandra Jagetia; Golgod Krishnamurthy Rajanikant
Journal:  Int Wound J       Date:  2011-08-31       Impact factor: 3.315

Review 4.  Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system.

Authors:  Jaewon Lee; Dong-Gyu Jo; Daeui Park; Hae Young Chung; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

5.  Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-α: a randomized placebo-controlled double-blind clinical trial.

Authors:  Nan Shao; Huixin Jia; Yiwen Li; Jingying Li
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

Review 6.  Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis.

Authors:  Meysam Gachpazan; Sadra Habbibirad; Hoda Kashani; Tannaz Jamialahmadi; Hamid Reza Rahimi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

8.  Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.

Authors:  Go Haraguchi; Hisanori Kosuge; Yasuhiro Maejima; Jun-Ichi Suzuki; Takasuke Imai; Masayuki Yoshida; Mitsuaki Isobe
Journal:  Intensive Care Med       Date:  2008-02-19       Impact factor: 17.440

9.  Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up.

Authors:  Pia Allegri; Antonio Mastromarino; Piergiorgio Neri
Journal:  Clin Ophthalmol       Date:  2010-10-21

Review 10.  The antioxidant response element and oxidative stress modifiers in airway diseases.

Authors:  Sekhar P Reddy
Journal:  Curr Mol Med       Date:  2008-08       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.